Johns Hopkins University has discovered daunorubicin derivatives reported to be useful for the treatment of cancer, including glioblastoma, diffuse midline glioma and diffuse intrinsic pontine glioma.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to RACα serine/threonine-protein kinase AKT targeting moiety through a linker reported to be useful for the treatment of prostate cancer.
Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have described cyclin-dependent kinase 12 (CDK12) inhibitors reported to be useful for the treatment of cancer.
Researchers from the University of Minnesota have presented the discovery and preclinical characterization of a novel potent inhibitor of multidrug resistance-associated protein 1 (MRP1), ZW-1226, that is being developed as a therapeutic candidate for the treatment of multidrug resistant (MDR) cancers.
Researchers from Qingdao University have presented data from a study that aimed to investigate the role of HIG1 hypoxia inducible domain family member 1B (HIGD1B) in gastric cancer (GC). The expression of HIGD1B was analyzed in GC and normal gastric tissues from multiple independent cohorts from public databases and verified using cell experiments.
Researchers from East China Normal University and Fudan University presented the discovery of a new oral compound, Z-526, being developed as a treatment to alleviate chemotherapy-induced cachectic muscle loss.
To be successful, CAR T-cells need a balance between being effective and overkill. Researchers from the University of Pennsylvania and Vittoria Biotherapeutics Inc. have eliminated the CD5 signaling pathway of their CAR Ts to prevent the immunosuppressive brake effect. In return, this improved their proliferation and antitumor activity in T cell lymphomas.
Stryker Corp. continued its recent buying spree with the purchase of Molli Surgical Inc., a company that develops wire-free soft tissue localization technology for breast-conserving surgery. Styker said Molli’s offerings strengthen its advancing surgical solutions in breast cancer care.
Immunotherapy-focused biotech company LTZ Therapetics Inc. raised $20 million in a series A round that will advance development of its myeloid engager pipeline to treat cancer and autoimmune diseases. Proceeds from the funds will accelerate development of lead asset LTZ-301, which is expected to enter the clinic in early 2025, LTZ founder and CEO Robert Li told BioWorld.
Radiopharmaceutical company Telix Pharmaceuticals Ltd. received a U.S. FDA refusal to file letter for its BLA seeking approval of renal cancer imaging agent TLX250-CDx (89Zr-DFO-girentuximab) for clear cell renal cell carcinoma (ccRCC).
RSS
